Novartis Oncology is committed to precision oncology treatment. Precision oncology is the evolving understanding of how cancers develop at a genomic level and our ability to develop drugs that hone in on those targets – ultimately leading to better patient outcomes. Our research, driven by a distinctive scientific and clinical strategy, focuses on unmet medical needs in the following disease pathways.
Advanced Breast Cancer
Neuroendocrine tumours (NETs)
Chronic Myeloid Leukaemia
Myelofibrosis and Polycythaemia Vera (MPNS)
Acute Myeloid Leukemia (AML)
Non Small Cell Lung Cancer
Renal Cell Carcinoma
Cell and Gene Therapy
Novartis Pharmaceuticals has created a dedicated unit focused on the development and commercialisation of cell and gene therapies. The portfolio aims to transform medical practice and help patients suffering from a variety of life-threatening diseases including bloodborne cancers, sickle cell disease, thalassaemias and other diseases of the blood by replacing, repopulating or resetting the immune system.
Cardiovascular, Renal & Metabolism
Novartis Cardiovascular, Renal & Metabolism therapeutic teams are passionate about research, development and quality manufacturing of novel therapies and solutions to reduce the burden of diseases in communities in the UK, and around the world. We focus our efforts on diseases that negatively affect the heart, kidney, liver and blood vessels with the goal of better patient outcomes.
Respiratory and Inflammation
At Novartis, we are focused on improving the lives of the millions of people affected by respiratory and inflammation diseases and continue to research, develop and launch innovative therapies which treat chronic obstructive pulmonary disease, chronic spontaneous urticaria and severe allergic asthma.
Immunology, Hepatology &Dermatology
Our Immunology, Hepatology & Dermatology franchise aims to transform patients’ lives by targeting progressive illnesses and treating co-morbidities in the specialty dermatology, rheumatology and transplantation fields. There remains a high, unmet medical need in these fields, and for patients with liver disease.
Novartis has a strong 60-year history in neuroscience. We currently offer patients and physicians a large portfolio of medicines encompassing migraine, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, epilepsy and attention deficit hyperactivity disorder (ADHD) treatments. We also have a pipeline in multiple sclerosis, Alzheimer’s disease and neuromuscular therapies. In our research, we leverage advances in human genetics, new imaging technologies and other novel approaches to better understand neurological disorders and continue bringing new drugs to patients in the UK and worldwide.
Novartis is dedicated to the research, development and manufacturing of ophthalmic medicines. The mission of Novartis in the field of ophthalmology is to discover, develop and manufacture innovative products to improve eye health and enhance people’s lives.
While a rare disease, by definition, affects a small fraction of the population, the collective impact of such diseases is huge. An estimated 3.5 million people in the UK will be affected by a rare disease at some point in their lives, but a significant proportion of these patients do not have access to the right care and treatment.1
At Novartis, we are focused on improving the lives of the many people affected by several rare diseases, including tuberous sclerosis complex (TSC), acromegaly and Cushing’s disease. We seek to research, develop and provide a range of innovative medicines to help address unmet medical needs, as well as provide solutions to help improve the lives of patients living with these rare diseases.